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Rapid and Long-Term Disappearance of CD4! T Lymphocyte
Responses Specific for Anaplasma Marginale Major Surface
Protein-2 (MSP2) in MSP2 Vaccinates following Challenge
with Live A. marginale1
Jeffrey R. Abbott,* Guy H. Palmer,* Kimberly A. Kegerreis,* Peter F. Hetrick,*
Chris J. Howard,† Jayne C. Hope,† and Wendy C. Brown2*
In humans and ruminants infected with Anaplasma, the major surface protein 2 (MSP2) is immunodominant. Numerous CD4!
T cell epitopes in the hypervariable and conserved regions of MSP2 contribute to this immunodominance. Antigenic variation in
MSP2 occurs throughout acute and persistent infection, and sequentially emerging variants are thought to be controlled by
variant-specific Ab. This study tested the hypothesis that challenge of cattle with Anaplasma marginale expressing MSP2 variants
to which the animals had been immunized, would stimulate variant epitope-specific recall CD4! T cell and IgG responses and
organism clearance. MSP2-specific T lymphocyte responses, determined by IFN-" ELISPOT and proliferation assays, were strong
before and for 3 wk postchallenge. Surprisingly, these responses became undetectable by the peak of rickettsemia, composed
predominantly of organisms expressing the same MSP2 variants used for immunization. Immune responsiveness remained in-
significant during subsequent persistent A. marginale infection up to 1 year. The suppressed response was specific for A. marginale,
as responses to Clostridium vaccine Ag were consistently observed. CD4!CD25! T cells and cytokines IL-10 and TGF-#1 did not
increase after challenge. Furthermore, a suppressive effect of nonresponding cells was not observed. Lymphocyte proliferation and
viability were lost in vitro in the presence of physiologically relevant numbers of A. marginale organisms. These results suggest that
loss of memory T cell responses following A. marginale infection is due to a mechanism other than induction of T regulatory cells,
such as peripheral deletion of MSP2-specific T cells. The Journal of Immunology, 2005, 174: 6702–6715.
P athogens in the genus Anaplasma express immunodomi-nant outer membrane proteins with defined conserved andvariable domains (1–6). Antigenic variation in Anaplasma
marginale major surface protein 2 (MSP2)3 and in the orthologous
MSP2/p44 protein of Anaplasma phagocytophilum, results in eva-
sion of the immune response and has been postulated to be re-
sponsible at least in part, for persistent infection in mammalian
reservoir hosts (6–20). Although the acute phase of A. marginale
infection peaks with levels of !109 rickettsiae per milliliter of
blood, persistent infection is characterized by recurrent subclinical
cycles of rickettsemia that range from 103 to 107 organisms per
milliliter (6, 7, 21–23). Each cycle of rickettsemia reflects the
emergence of organisms that express antigenically variant MSP2
(7). Antigenic variation in MSP2, and in a related surface protein,
MSP3, occurs by gene conversion of whole pseudogenes and small
segments of pseudogenes into single expression sites, providing an
efficient mechanism to generate the large number of variants seen
during sequential cycles of persistent infection (8, 12, 13, 24).
The control of the sequential rickettsemic cycles during persis-
tent infection is associated with development of a variant-specific
IgG response and, in particular, IgG2 (7). In addition, MSP2 con-
tains numerous MHC class II-restricted CD4! T cell epitopes in
both the highly conserved N- and C-terminal domains as well as in
the variant-specific central hypervariable region (HVR) (10, 11,
25, 26). This rich source of epitopes may serve to induce T cell
help for generation of variant-specific Ab and control of rickett-
semic cycles during persistent infection. In recent studies, we have
used cattle immunized with purified MSP2 to define both the T and
B lymphocyte epitopes in a specific set of MSP2 variants (10, 26).
This allowed us to control the variants used for challenge in the
context of the continual generation of new variants that occurs
during actual infection. T cell epitopes were also recently mapped
in 16 MSP2 vaccinates representing 10 different MHC class II
DRB3 alleles. IgG Ab responses were directed against epitopes
predominantly located within the HVR, whereas CD4! T cell pro-
liferative and IFN-" responses were directed against multiple
epitopes evenly distributed in the highly conserved and hypervari-
able regions (25). In the present study, we address stimulation and
maintenance of anamnestic responses by specific MSP2 variants
following infection. This study tested the hypothesis that challenge
of cattle with A. marginale expressing MSP2 variants to which the
animals had been immunized, would stimulate variant epitope-spe-
cific recall CD4! T cell and IgG responses and variant-specific
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organism clearance. In this paper, data are presented that support
rejection of this hypothesis and, in contrast, demonstrate a newly
discovered immune modulation whereby Ag-specific T cell re-
sponsiveness is lost upon rickettsial challenge.
Materials and Methods
Animals and immunization
Cattle that were seronegative for A. marginale determined by an MSP5-
specific competitive inhibition ELISA (27) were previously vaccinated
with Vision 7 killed Clostridium spp. including Clostridium chauvoei,
Clostridium septicum, Clostridium novyi, Clostridium sordellii, and Clos-
tridium perfringens types C&D (Intervet) and 2–3 mo later with gel-puri-
fied native MSP2 (28). Four calves per group were immunized six times
s.c. with 50 #g of MSP2 adsorbed in 2 mg of alum (Rehydragel, low
viscosity sterile gel; Reheis) with either 10 #g of human IL-12 (kindly
provided by Genetics Institute, Cambridge, MA) (animal nos. 01B71,
01B75, 01B76, and 01B82) or 1 mg of CpG oligodeoxynucleotide (ODN)
2006 (Oligos, Etc.) (animal nos. 01B78, 01B79, 01B81, and 01B87) as
adjuvants (28). Negative control animals received alum and CpG ODN
alone (animal nos. 01B73, 01B74, 01B84, and 01B89). All of the protocols
in this study were reviewed and approved by the Washington State Uni-
versity Institutional Animal Care and Use Committee.
Challenge of immunized cattle
A splenectomized calf C949BL was inoculated i.v. with 0.2 ml of blood
stabilate from calf C831BL infected with the Florida strain of A. margi-
nale, the same batch of blood used for generating MSP2 for immunization,
to ensure that the same MSP2 variants used for immunization were rep-
resented in the challenge inoculum. Twenty-six days postinfection (DPI),
fresh blood was used for challenging the MSP2-immunized calves. To
control the number of infectious organisms and to minimize contamination
of bacterial proteins from dead organisms often found in frozen stabilate,
the immunized and control calves were inoculated i.v. with "3 # 103 live
organisms in 1 ml of PBS (pH 7.2). Microscopic examination of Wright-
Giemsa-stained blood smears was performed daily to detect and quantify
the level of A. marginale infection in the challenged animals. Packed cell
volumes (PCVs) and rectal temperatures were also recorded daily.
PBMC and sera were collected from 5 mo following the last immuni-
zation (immediately before challenge), weekly thereafter until 2 mo fol-
lowing peak rickettsemia, and occasionally during persistent infection over
the next year, and stored in liquid nitrogen (PBMC) or at $20°C (sera) for
later use in T cell and Ab assays.
Sequencing of expression site msp2
Infected erythrocytes were washed three times in PBS with removal of the
buffy coat after each wash, and genomic DNA was extracted from infected
erythrocytes using the PureGene kit (Gentra Systems). The complement of
msp2 variants was analyzed in blood used for immunization (animal no.
831), blood used for challenge (animal no. 949), and blood from three
immunized animals (nos. 76, 81, and 82) and two control animals (nos. 74
and 89) before, during, and after peak rickettsemia. Forward msp2 primer
(ATG AGT GCT GTA AGT AAT AGG AAG) or open reading frame 2
forward primer (TCC TAC CAA GCG TCT TTT CCC C) and msp2 re-
verse primer (TTA CCA CCG ATA CCA GCA CAA) with Taq polymer-
ase (Roche Applied Science) were used to amplify the msp2 HVRs. All
primer sequences correspond to the msp2 operon sequence (GenBank ac-
cession no. AF200927), and all msp2 sequences in the resulting PCR frag-
ments correspond to the expression site (9). PCR was performed with
genomic DNA and fragments cloned into the pCR4 TOPO vector (Invitro-
gen Life Technologies). Plasmid DNA was isolated, and inserts were se-
quenced in both directions with BigDye terminator chemistry on an ABI
automated sequencer (PerkinElmer Applied Biosystems). Seventeen clones
from blood used for immunization (animal no. 831) and 28 clones from
blood used for infection (animal no. 949) were sequenced. In addition,"30
clones were sequenced from each of the five animals, nos. 74, 76, 81, 82,
and 89, at five time points spanning the period of peak rickettsemia. Thirty
clones were attempted to ensure to a 95% confidence that all msp2 variants
expressed at least 10% of the time in the population were represented,
according to the test of binomial proportions. Sequences of msp2 from the
earliest time point for animals nos. 74 and 76 were not obtained due to low
numbers of organisms at that time. Sequences were compiled and analyzed
using the Vector NTI (InforMax) software package. GenBank accession
numbers for MSP2 variants F–Y are AY847664–AY847683.
Preparation of A. marginale, MSP2 Ags, and MSP2-derived
peptides
Cryopreserved A. marginale Florida strain-infected bovine erythrocytes
were prepared as previously described (28, 29). Native MSP2 was purified
from sonicated A. marginale organisms subjected to preparative SDS gra-
dient (10–20%) PAGE (30, 31). One lane of the gel with molecular mark-
ers was cut, transferred, and blotted with MSP2-specific mAb to orient the
MSP2 on the gels. The MSP2 band was excised from multiple gels, and the
protein was electroeluted from the gel fragments as described previously
(31). Eluted protein was concentrated and dialyzed against PBS and puri-
fied a second time on preparative gels. MSP2 was verified by immuno-
blotting to be reactive with MSP2-specific mAb AnaF19E2 but not reactive
with Abs that recognize A. marginale MSP1, MSP3, MSP4, and MSP5
(28). Imbricated 24- to 30-mer peptides that overlap by 10–20 aa and span
the Florida strain MSP2 A variant sequence reported in GenBank (acces-
sion no. AY138954) were synthesized (10, 26). The MSP2 A variant was
expressed from DNA clone 1-7, the most common variant transcript iden-
tified in the blood used for MSP2 immunization (10). The amino acid
sequences of these peptides were reported previously (10, 26).
IFN-" ELISPOT assays
Cryopreserved PBMC from immunized and control animals, obtained at
the indicated days postchallenge, were analyzed for IFN-"-secreting cells
using an ELISPOT assay as described (28) with some modifications. After
blocking and washing the plates, 0.5 # 106 PBMC were added in 100-#l
volumes containing complete RPMI 1640 medium (11) alone, or with 10
and 1 #g/ml uninfected bovine erythrocyte membranes (URBC), A. mar-
ginale Florida strain homogenate, native MSP2, or MSP2-derived peptides
(Table I). A mixture of 1.0 #g/ml PHA-P (Sigma-Aldrich), 0.01 ng/ml
human IL-12 (Genetics Institute), and 0.5 ng/ml human IL-18 (PeproTech),
shown to stimulate high levels of IFN-" in bovine PBMC (32), was used
as a positive control. After incubation for 40 h at 37°C, the plates were
washed, developed, and dried overnight. Spots were visualized using an
ELISPOT reader (Cell Technology) and AID 2.9 software (AutoImmun
Diagnostika). For each PBMC sample, the mean number of spots in the
negative control wells was subtracted from the mean number of spots in
test wells to determine the mean number of A. marginale MSP2-specific
IFN-"-secreting cells or spot-forming cells (SFC). Results are presented as
the mean number of SFC per 106 PBMC.
Lymphocyte proliferation assays
Proliferation assays were conducted in replicate wells of round-bottom
96-well plates (Costar) for 6 days, essentially as described (26, 33). PBMC
(2# 105) isolated at the same time as for the ELISPOT assay were cultured
for 6 days in triplicate wells with dilutions of 10, 1, and 0.1 #g/ml Ags
identical with those used in the ELISPOT assay. In addition to the PHA,
IL-12, and IL-18 mixture, bovine T cell growth factor (TCGF) at a final
dilution of 10% was included as a positive control for proliferation. The
PBMC were radiolabeled for the last 18 h of culture with 0.25 #Ci of
[3H]thymidine (DuPont, New England Nuclear) and harvested onto glass
filters, and radionucleotide incorporation was determined using a Betaplate
1205 liquid scintillation counter (Wallac). Results are presented as the
mean cpm of triplicate cultures % 1 SD.
MSP2-specific IgG titers
ELISAs were used to determine MSP2-specific IgG1 and IgG2 titers as
described (28) with the following changes. Sera (100 #l) from the 12 study
cattle diluted from 1/10 to 1/100,000 were added per well, followed by 100
#l/well of 1 #g/ml bovine IgG1-specific mAb BIG 715A (WSU Mono-
clonal Center) or a 1/100 dilution of bovine IgG2-specific mAb K192 4F10
(Serotec). These mAb concentrations bound to equivalent amounts of pu-
rified bovine IgG1 and IgG2 (Serotec). The OD405 were determined using
a Titertek Multiscan MCC/340 microplate reader (MTX Lab Systems).
Cytokine ELISAs
IL-10, TGF-$1, and IL-4 ELISAs were used to analyze supernatants from
PBMC grown in culture for 72 h with 5 #g/ml MSP2 for the secretion of
cytokines. The IL-10 ELISA was done as previously described (34) with
the following modifications. Black 96-well microplates (Porvair) were in-
cubated overnight at 4°C with capture mAb CC318 at 6 #g/ml in coating
buffer. All additional incubations were at room temperature. The plates
were washed with PBS containing 0.5% Tween 20 (PBST) and blocked
with PBST containing 1% BSA for 1 h. Following blocking, 100 #l of cell
culture supernatants were added to each well and incubated for 1 h. Fol-
lowing six washes with PBST, 100 #l of 2 #g/ml biotin-labeled secondary
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mAb CC320, was added to each well and incubated for an additional 1 h.
The plates were washed six times with PBST, and 100 #l of the Super
Signal ELISA Femto Maximum Sensitivity substrate (Pierce) was added,
and the plates were evaluated within 5 min. The relative light unit value
was read on Betaplate 1205 liquid scintillation counter and luminometer
(Wallac).
The IL-4 ELISA was performed using the same protocol described for
IL-10 with the use of bovine IL-4-specific mAbs. mAb CC314 was used for
coating, and biotinylated mAb CC313 was used for detection (61).
The TGF-$1 ELISA was performed per manufacturer’s protocol no.
TB196 (Promega). Samples were diluted 1/16 in 1# TGF-$1 sample buffer
and then acidified for 15 min by addition of 1.0 #l of 1 N HCl/50 #l of
sample. The samples were neutralized by adding 1.0 #l of 1 N NaOH/50
#l of sample until the sample pH was 7.6. Immulon II 96-well ELISA
microplates (Dynax Technologies) were coated with 100 #l of 1 #g/ml
anti-human TGF-$1 “coat mAb” in carbonate coating buffer (0.025 M
sodium bicarbonate, 0.025 M sodium carbonate, pH to 9.7) overnight at
4°C. The plates were emptied and blocked with 270 #l of 1# TGF-$1
blocking buffer for 35 min at 37°C. After washing three times with PBST,
100 #l of sample supernatants was added and incubated at room temper-
ature for 90 min while shaking. After washing six times with PBST, the
plates were incubated with “anti-TGF-$1 pAb” at room temperature for
2 h, while shaking followed by six additional washes with PBST. To each
well, 100 ml of TGF-$1 HRP conjugate was added and incubated for 2 h
at room temperature while shaking. After washing six times with PBST,
100 #l of tetramethylbenzidine solution was added to each well and incu-
bated for 15 min. To each well, 100 #l of 1 N HCl was added, and the
OD450 was determined.
Flow cytometric analysis
PBMC were stained for surface expression of CD4 (mAb IL-A11), CD8
(mAb 7C2B), and "% TCR (TCR1) (mAb GB21A). Secondary goat anti-
mouse isotype-specific Abs conjugated with PE were used for visualizing
CD4, CD8, and "% TCR1-staining cells. For two-color analysis, CD25-
specific mAb CACT 116A and goat anti-mouse isotype-specific, FITC-
conjugated secondary Abs were used. All primary mAb were obtained
from the Washington State University Monoclonal Antibody Center. Sec-
ondary Abs were obtained from Caltag Laboratories. Samples were ana-
lyzed using a FACSCalibur flow cytometer (BD Biosciences). At least 5#
105 cells were used for staining, and 10,000 cells were acquired using BD
Biosciences CellQuest software.
Table I. Prevalence of A. marginale msp2 variants
Number and Letter Designation of msp2 Variants Sequenced
Animal 831 Animal 949
DPI
Animal 82 Animal 76 Animal 81 Animal 74 Animal 89
Immunization groupa Challenge groupb MSP2 ! IL-12 groupc MSP2 ! IL-12 group MSP2 ! CpG group CpG only group CpG only group
10-A 19-A 24 6-A 7-A 10-A
4-C 3-D 1-D 1-D 1-Q
1-D 1-F 1-G 1-F
1-E 1-G 2-G
1-F 1-H
1-G 1-I
1-I 2-O
31 20-A 18-A 28-A 16-A 18-A
2-D 1-F 1-D 12-D 5-D
1-C 11-G 1-G 3-E
6-G 1-K 1-I
1-K
2-Q
1-W
38 12-A 21-A 6-A 28-A 3-A
1-B 7-G 1-C 6-D 2-C
1-C 3-D 12-D
2-D 1-F 3-E
10-G 9-G 2-G
1-J 2-I 2-K
1-K 2-K 1-R
1-Q 4-Q 1-U
1-R 1-W
45 9-A 28-A 15-C 5-A 1-F
6-B 2-E 2-G 27-D 16-G
1-C 1-F 1-R 5-K
2-D 3-G 2-N
6-G 3-R
2-J
1-K
52 1-B 16-A 4-C 5-A 2-C
22-G 1-C 2-D 1-C 1-D
1-L 2-D 6-G 20-D 12-G
1-M 5-E 2-N 2-G 6-N
2-N 2-F 2-O 1-V 1-R
1-O 4-G 2-Q 1-V
2-R 1-P 3-R 4-Y
1-T
a msp2 variants and relative number sequenced from blood used to purify MSP2 protein for immunization.
b msp2 variants and relative number sequenced from blood used for challenge of eight immunized and four control animals.
c msp2 variants and relative number sequenced from blood of challenged animals. Bolding indicates variants identical to msp2 variants present in the blood used to purify
the MSP2 for immunization.
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Coculture of responding and nonresponding PBMC
Proliferation assays mixing responding (pre-peak rickettsemia) and nonre-
sponding (peak rickettsemia) PBMC were performed as described above
with the following changes. A fixed number of responding cells numbering
either 0.5 # 105 PBMC/well or 1 # 105 PBMC/well were cultured with
varying numbers of nonresponding PBMC, which were 4-, 2-, 1-, 0.5-, and
0-fold the number of responding cells. As a control for total numbers of
cultured cells, responding PBMC were cultured at a number equal to that
of the total number of responding plus nonresponding PBMC.
Culture of enriched CD4! T cells with naive APC
CD4! T cells were positively selected from responding PBMC and non-
responding PBMC taken at the peak of rickettsemia from cattle 71 and 76,
and tested for Ag-specific proliferation using APC prepared from nonin-
fected cattle that expressed a half-matched, homozygous MHC class II
haplotype. PBMC frozen at 1 wk postchallenge from animal 71 and at 2 wk
prechallenge from animal 76 (responding cells) and at 6 wk postchallenge
from animal 71 and at 5 wk postchallenge from animal 76 (nonresponding
cells) were used. CD4! T cells were positively selected from thawed cells
following incubation with anti-CD4 mAb ILA-11 and goat anti-mouse
IgG-coated MACS MicroBeads beads following the manufacturer’s in-
structions (Miltenyi Biotec). Following several washes in complete RPMI
1640, the CD4! T cells (1 # 105 cells/well) were cultured overnight in
U-bottom 96-well plates in 100 #l of complete RPMI 1640 with 1 # 105
irradiated PBMC from the donor animal half-matched at MHC class II. The
next day, the plates were centrifuged at 900 # g, and "75 #l of superna-
tant was replaced by fresh medium to remove residual anti-CD4 mAb. Ag
was then added to triplicate wells, and the cells were incubated for an
additional 4 days and pulsed with [3H]thymidine during the last 18 h of
culture. Cells were harvested and counted, and the data are presented as
mean cpm % 1 SD. FACS analysis of the CD4! positively selected cells
revealed a mean of 78% CD4! T cells, 18% CD8! cells, and 4% CD14!
cells.
MHC class II DRB3 alleles were defined by PCR-restriction fragment
length polymorphism of exon 2 and by sequencing the DRB3 cDNAs (25,
35). APC from cattle 98B61 (DRB3 8/8) and 201 (DRB3 22/22) were used,
respectively, to present Ag to CD4! T cells from MSP2-immunized cattle
71 (DRB3 8/14) and 76 (DRB3 22/21).
Inhibition of lymphocyte viability and proliferation by A.
marginale
Initial bodies were purified essentially as described (29). Blood from an A.
marginale-infected animal with 23% infected erythrocytes was washed five
times with PBS and centrifuged at 30,000 # g for 30 min after each wash.
Infected erythrocytes were resuspended in PBS containing Complete Mini
protease inhibitors following manufacturer’s instructions (Roche). A. mar-
ginale organisms were released from infected erythrocytes by sonication
with the Sonifier Cell Disruptor 350 (VWR Scientific) at an output control
setting of 4 at 100% duty cycle, followed by centrifugation at 1500# g for
15 min. The pelleted organisms were resuspended in PBS and stored at
$20°C. Protein determination revealed that this preparation contained 16
mg/ml protein. Cryopreserved PBMC (2# 105 cells/well) from an A. mar-
ginale-naive donor cow were thawed, washed, and cultured for 3 days with
10% TCGF with or without A. marginale using "3–50 # 106 infected
erythrocyte equivalents per milliliter. The cells were either pulsed with
[3H]thymidine, harvested, and counted, or triplicate wells were pooled and
cell viability was determined by trypan blue dye exclusion. Results are
presented as mean cpm ! 1 SD of triplicate cultures or mean number of
viable cells/milliliter.
Data analysis and statistics
All statistical tests were done with Number Cruncher Statistical Software
(NCSS2001), version 2.00.0185. The proportion of the msp2 A variant in
the organisms used to prepare MSP2 for immunization and for challenge
was compared by the Fisher Exact test. Clinical parameters of the immu-
nized groups were compared by Kruskal-Wallis rank sum analysis with the
control group (&& 0.05). Correlation of IgG titers with clinical parameters
was determined using multivariate linear regression and Spearman rank
correlation. One-way ANOVA with Bonferonni correction for multiple
comparisons (& & 0.05) was used to determine significant ELISPOT and
proliferation responses as compared with medium, and to determine sig-
nificant differences in CD25! T lymphocyte populations. Paired two-tailed
t tests were used to determine significance differences in cytokine levels
between responding and nonresponding PBMC.
FIGURE 1. Predicted amino acid sequences for msp2 variants identified in this study. msp2 genes were cloned from blood used to purify MSP2 for
immunization (A and B), from blood used for challenge of the vaccinates and control calves (B and C), and from blood of five of the challenged animals
at the indicated time points before, during, and after peak rickettsemia (D). A contains msp2 variant sequences found in the immunogen, but not the
challenge blood. B contains msp2 variant sequences common to both immunogen and challenge blood. C contains msp2 variant sequences found in the
challenge blood, but not the immunogen. All sequences begin at aa 183 corresponding to the msp2 11.2 genomic DNA clone (15).
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FIGURE 2. Rickettsemias and PCVs of eight immunized and four control cattle during acute anaplasmosis. Cattle were challenged 5 mo postimmu-
nization with "3000 live A. marginale organisms. Rickettsemias and PCVs were measured daily for control animals immunized with alum and CpG ODN
2006 only (A–D) and animals immunized with MSP2, alum, and either IL-12 (E–H) or CpG ODN 2006 (I–L). Animal numbers are indicated on each panel.
Rickettsemia (left axis) is reported as number of infected erythrocytes per milliliter of whole blood as determined by microscopic evaluation of daily blood
smears. Daily PCV (right axis) was used to evaluate anemia during infection. †, Indicates days when the temperature was '102°F. ‡, Indicates days when
the temperature was '103°F.
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Results
Comparison of MSP2 variants in the MSP2 immunogen and
challenge organisms
The relationship between msp2 variants in the A. marginale-in-
fected blood used as a source of MSP2 immunogen and the msp2
variants expressed by the organisms in the blood used for chal-
lenge was determined by sequencing the msp2 single expression
site in these organisms (Fig. 1). In the organisms used as a source
of preparing MSP2, 10 of the 19 msp2 clones sequenced were
variant A, 4 were variant C, and 5 additional minor variants were
each represented by a single clone (Table I). The A. marginale
used for challenge was also composed predominantly of the msp2
A variant (19 of 28 clones) and contained 6 additional minor vari-
ants (Table I). Although amplification of DNA by PCR to deter-
mine the relative frequency of msp2 variants may introduce bias,
previous studies have shown a positive correlation in relative lev-
els of msp2 variants amplified by PCR with levels of msp2 ex-
pression site genomic DNA, msp2 mRNA, and MSP2 protein (12,
36). In the present study, no statistically significant difference was
found in the frequency of the msp2 A variant in the organisms used
to prepare native MSP2 for immunization and those used for chal-
lenge ( p & 0.365). The predicted amino acid sequences of the
HVRs of all msp2 variants are shown in Fig. 1, A–C. Variants A,
B, C, D, and E have been previously reported (GenBank accession
nos. AY138954–AY138958) (10). Two minor msp2 variants (H
and O) were present in the challenge organisms that were not
found in the MSP2 immunogen (Fig. 1A), and two minor variants
(C and E) were present in the immunogen but not detected in the
challenge organisms (C).
Challenge of MSP2-immunized cattle with live A. marginale
Following challenge with "103 live A. marginale organisms, all
animals had microscopically measurable rickettsemia by 25 DPI
(Fig. 2). Ten of the 12 animals had levels of rickettsemia exceed-
ing 108 infected erythrocytes per milliliter of blood at the peak of
infection, "5–6 wk postchallenge. The remaining two animals,
one from each vaccination group, had '107 infected erythrocytes
per milliliter of blood. Clinical parameters including peak rickett-
semia levels, days to peak rickettsemia, days to detection of rick-
ettsemia, days to 108 infected erythrocytes per milliliter, and the
duration of the rickettsemia peak varied from animal to animal, but
there were no significant differences in these parameters of infec-
tion between immunized and control groups (Fig. 2).
Analysis of msp2 variants that arose following A. marginale
challenge
One possible explanation for the lack of protection in MSP2 vac-
cinates is that MSP2 variants unique to the challenge inoculum
could have evaded the immune response and expanded rapidly in
the immunized animals, causing acute rickettsemia. To examine
this possibility, "30 msp2 variants were cloned and sequenced
from three immunized and two control cattle at five time points
spanning the peak and resolution of acute rickettsemia (Table I).
The relative frequencies of the msp2 variants identified during
acute rickettsemia in the five animals are shown in Table I. Fig. 1D
shows only sequences of unique msp2 variants that arose during
acute rickettsemia in the five animals examined. At 24 DPI, which
was before consistent microscopic detection of rickettsia, the msp2
A variant was the predominant variant in each animal, regardless
of immunization status (Table I). At 31 DPI, the msp2 A variant
still predominated in the blood of all five animals tested. Interest-
ingly, one vaccinate (animal 76) and one control (animal 74) had
not completely cleared the msp2 A variant by 52 DPI (Table I),
when rickettsemia had dropped. Even though the other three ani-
mals succeeded in clearing the msp2 A variant by 52 DPI, the
predominant variants throughout all time points were msp2 vari-
ants present in the immunogen (Table I). Thus, the acute rickett-
semia in MSP2 vaccinates was apparently not due to the emer-
gence of minor or novel MSP2 variants.
MSP-specific IgG responses
To determine whether anamnestic MSP2-specific IgG responses
occurred following challenge of immunized animals, IgG1 and
IgG2 titers were measured before challenge and at several time
points thereafter (Table II). Before challenge, all immunized, but
not control, animals had measurable IgG1 titers, and all but one
had measurable IgG2 titers. After challenge, the immunized ani-
mals developed higher titers than the controls. However, the Ab
titers in both immunized and control animals peaked at the time of
peak rickettsemia, then tapered off over 2 mo following resolution
Table II. A. marginale MSP2-specific IgG1 and IgG2 titers in the sera of immunized and control animals before and during acute anaplasmosis
Group and Calf No.
IgG1 Titera IgG2 Titera
Prechallenge Prepeak Peak Postpeak Prechallenge Prepeak Peak Postpeak
0 DPI 21–24 DPI 36–38 DPI 92–97 DPI 0 DPI 21–24 DPI 36–38 DPI 92–97 DPI
MSP2 ! IL-12 ! alum
71 100 100 10,000 1,000 10 10 1,000 500
75 10 10 5,000 1,000 10 10 10 10
76 100 100 10,000 1,000 500 500 10,000 1,000
82 1,000 5,000 50,000 10,000 10 100 10 10
MSP2 ! CpG ! alum
78 100 100 100 1,000 100 100 100 1,000
79 1,000 500 10,000 1,000 100 100 100 100
81 100 500 1,000 500 0 0 0 0
87 10 1,000 5,000 1,000 10 10 10 10
CpG ! alum only
73 0 10 5,000 100 0 0 0 0
74 0 10 100 100 0 0 0 10
84 0 10 100 100 0 0 10 10
89 0 10 1,000 500 0 0 0 0
a Titers are expressed as the reciprocal of the highest dilution of serum that reacted by ELISA.
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of clinical disease, and remained at or higher than prechallenge
levels, which is consistent with persistent infection. Also, as seen
previously (28), IgG1 levels overall were significantly higher than
IgG2 levels throughout acute infection. These results also show
that there was no correlation of MSP2-specific IgG1 and IgG2 Ab
titers and level of rickettsemia; however, the cattle with the lowest
levels of rickettsemia were the only animals with prechallenge
IgG2 titers of !100.
FIGURE 3. Comparison of CD4! T cell epitopes recognized by cattle before and following A. marginale challenge by IFN-" ELISPOT assay.
Representative data from PBMC from animal 71 from the IL-12 adjuvant group (A–D) and animal 73 from the control group (E–H) are presented. PBMC
were assayed for responses to the mixture of PHA plus IL-12 plus IL-18 (PHA), and 10 #g/ml A. marginale lysate, whole MSP2, or overlapping peptides
spanning MSP2. Assays were done simultaneously with cryopreserved PBMC obtained at the indicated time points: before challenge (A and E), following
challenge, but before peak rickettsemia (B and F), at peak rickettsemia (C and G), and 2 mo following peak rickettsemia (D and H). Data are presented
as the mean number of SFC ! 1 SD of triplicate cultures with Ag minus the mean number of SFC of triplicate cultures with medium, and are reported
as mean number of SFC/106 PBMC.
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Comparison of MSP2-specific CD4! T cell responses before
and after challenge by IFN-" ELISPOT assay
To determine whether challenge evoked an anamnestic CD4! T
cell response specific for conserved or variable MSP2 epitopes in
MSP2 vaccinates, IFN-" ELISPOT assays were performed using
PBMC obtained before and following challenge. A. marginale,
native MSP2, and overlapping peptides spanning the predominant
MSP2 A variant were used for stimulation of PBMC. We previ-
ously demonstrated that CD4! T cells in PBMC of these MSP2-
immunized animals were the responding cells (25). Assays for
each individual were done simultaneously using PBMC obtained
immediately before challenge (5 mo after immunization), 21–23
DPI (before peak rickettsemia), 36–38 DPI (peak rickettsemia),
and 92–94 DPI (post-peak rickettsemia).
Before peak rickettsemia, the IFN-" ELISPOT responses to
MSP2-derived peptides were overall similar in magnitude to those
seen following MSP2 immunization in all MSP2-immunized ani-
mals, suggesting that challenge did not boost the pre-existing re-
sponse (Fig. 3 and Table III). What was more interesting, however,
was the finding that Ag-specific CD4! T cell responses deter-
mined at the time of peak rickettsemia and at all time points there-
after measured in individual animals for 7 mo to 1 year postchal-
lenge, were severely decreased to background or near background
levels for all animals and Ags tested (Figs. 3 and 4). Furthermore,
none of the four control animals generated a significant CD4! T
cell response to A. marginale, MSP2, or any of the MSP2-derived
peptides at the time points examined postchallenge for up to 3 mo
(Fig. 3). In contrast to the MSP2-specific response, similar levels
of response to the mixture of PHA, IL-12, and IL-18 were main-
tained throughout the course of infection. These results were ob-
tained in at least two independent assays. Fig. 3 illustrates these
results for PBMC obtained from immunized animal 71 and control
animal 73 at two time points before peak rickettsemia (Fig. 3, A
and B; and E and F, respectively), at peak rickettsemia (C and G),
and following peak rickettsemia (D and H). Table III summarizes
the ELISPOT assay results for all animals, presenting only data for
those conserved and hypervariable region peptides that induced
strong responses before peak rickettsemia in the majority of ani-
mals. Antigenic variation in MSP2 does not explain the sudden
loss of response, because the decrease in CD4! T cell responses
included those responses to peptides from both conserved as well
as HVRs.
Comparison of IFN-" ELISPOT and proliferation assays to
MSP2 and to Clostridium vaccine Ag
We recently showed a significant correlation between proliferation
and IFN-" ELISPOT responses by PBMC from these MSP2 vac-
cinates to A. marginale, MSP2, and MSP2-derived peptides (25).
Table III. Comparison of IFN-"-secreting CD4! T lymphocytes in PBMC before and after challenge: the percentage of SFC in PBMC obtained
postchallenge relative to the number of SFC obtained prechallenge in the animalsa
Antigen
IL-12 Animal Group CpG Animal Group
Animal
71
Animal
75
Animal
76
Animal
82
Animal
78
Animal
79
Animal
81
Animal
87
A. marginale Prechallenge (no. of SFC per 106 PBMC)b 587 198 125 829 150 231 73 723
Prepeak (%)c 189 120 102 33 110 316 100 50
Peak (%) 2 80 220 0 41 6 24 3
Postpeak (%) 4 53 74 17 36 17 124 13
MSP2 Prechallenge (no. of SFC per 106 PBMC) 1404 933 663 855 752 527 181 261
Prepeak (%) 125 93 105 123 97 185 96 150
Peak (%) 8 32 12 8 47 5 29 13
Postpeak (%) 7 4 8 16 11 0 0 8
P7 Prechallenge (no. of SFC per 106 PBMC) 67 343 66 935 148 188 16 126
Prepeak (%) 174 79 311 87 106 190 271 235
Peak (%) 1 13 0 0 13 2 0 5
Postpeak (%) 0 3 15 12 0 0 129 0
HV3 Prechallenge (no. of SFC per 106 PBMC) 417 417 555 769 180 57 135 9
Prepeak (%) 112 133 125 118 123 309 36 262
Peak (%) 0 0 3 1 89 24 17 300
Postpeak (%) 1 0 5 8 21 74 29 108
HV4 Prechallenge (no. of SFC per 106 PBMC) 921 601 173 647 311 191 231 63
Prepeak (%) 92 119 160 90 162 102 21 6
Peak (%) 2 0 15 10 118 2 13 26
Postpeak (%) 2 0 10 19 8 24 28 10
P10 Prechallenge (no. of SFC per 106 PBMC) 391 649 47 1027 210 60 82 55
Prepeak (%) 142 112 120 51 164 180 128 305
Peak (%) 8 24 17 3 0 18 7 0
Postpeak (%) 5 10 64 8 6 0 116 22
P13 Prechallenge (no. of SFC per 106 PBMC) 131 269 594 1197 510 71 97 105
Prepeak (%) 72 109 115 56 123 75 20 275
Peak (%) 9 24 9 8 10 9 12 0
Postpeak (%) 2 0 14 7 7 25 0 2
a Cryopreserved PBMC from immunized or control animals were stimulated for 40 h with 10 #g/ml A. marginale lysate, whole MSP2, or MSP2-derived peptides in the IFN-"
ELISPOT assay. Results are presented as mean number of SFC per 106 PBMC (prechallenge) after subtracting the mean number of SFC in cultures with medium. Responses
!150 SFC per 106 PBMC are considered significant and are indicated in bold.
b Prechallenge—mean number of SFC per 106 PBMC stimulated by the indicated Ag. Peptides P7, P10, and P13 are from conserved regions, and HV3 and HV4 are from
the central variable region of MSP2.
c Postchallenge—the percentage of the prechallenge number of SFC per 106 PBMC.
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Nevertheless, to address the possibility that following A. margi-
nale infection, the response changed from a predominant Th1-like
response to a predominant Th2-like response that could not be
detected by the IFN-" ELISPOT assay, proliferation and IFN-"
ELISPOT assays were conducted simultaneously with the same
aliquots of cells. Consistent with the results using the ELISPOT
assay, proliferative responses to A. marginale, MSP2, and all
MSP2-derived peptides were severely decreased in all eight vac-
cinates at the peak of infection and thereafter, whereas the re-
sponse to the PHA, IL-12, and IL-18 was always observed (rep-
resentative data for MSP2-immunized animal 71 are shown in Fig.
4, D–F).
To further determine whether the impaired T cell response to A.
marginale and MSP2 was Ag specific or reflected a generalized
immune suppression, Clostridium spp. Ag, which was used to vac-
cinate the calves before MSP2 immunization, was also included in
the assays. Unlike the responses to A. marginale and MSP2, the
response to Clostridium Ag was significant at all time points (Fig.
4). In addition, no significant responses to MSP2-derived peptides
were seen (Fig. 4, E and F). Similar results were obtained for all
immunized animals tested at various time points up to 7–12 mo
postinfection (data not presented), and suggest that the impaired
response to MSP2 is long-lived and does not reflect a generalized
immune suppression.
Quantitation of CD25!CD4! T cells by FACS
Regulatory T cells have not been defined in cattle. Nevertheless, to
evaluate the potential role of CD25!CD4! T regulatory cells in
the loss of MSP2-specific responses following challenge,
CD25!CD4! T cells were analyzed in PBMC from immunized
and control animals by two-color flow cytometry (Table IV). Al-
though the differences in the percentage of CD25!CD4! T cells in
PBMC varied between individual animals, when data for all ani-
mals were compared, no significant differences in the percentage
of CD25!CD4! T cells, expressed as either a percentage of total
CD4! T cells or of total CD25! T cells, were observed during the
course of infection (data not shown).
FIGURE 4. Comparison of IFN-" ELISPOT and proliferation assays using PBMC obtained before and following A. marginale challenge. PBMC were
obtained from animal 71 at the indicated time points, cryopreserved, and assayed simultaneously for IFN-"-secreting cells (A–C) or proliferation (D–F).
PBMC were stimulated with PHA plus IL-12 plus IL-18 (PHA), or 10 #g/ml A. marginale lysate, whole MSP2, and MSP2-derived peptides, or Clostridium
vaccine Ag diluted 1/100 and 1/1000. Data are presented as the mean number of SFC ! 1 SD of triplicate cultures with Ag minus the mean number of
SFC of triplicate cultures with medium, and are reported as the mean number of SFC/106 PBMC (A–C), or as the mean cpm ! 1 SD of triplicate cultures
(D–F).
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Comparison of IL-10, TGF-$1, and IL-4 production by
responding and nonresponding PBMC
IL-10 and TGF-$1 are cytokines produced by subsets of regulatory
T cells in mice and humans (37–40). Therefore, to investigate a
potential role of these cytokines either in the loss of MSP2-specific
T cell responses following challenge or in a switch from a Th1 to
a Th2 response, IL-10, TGF-$1, and IL-4 levels in supernatants of
PBMC cultured for 72 h with MSP2 were determined by ELISA.
There was no significant increase in IL-10, TGF-$1, or IL-4 pro-
duction by PBMC obtained at the peak of infection compared with
PBMC obtained before challenge (Tables V and VI). In fact, there
was significantly less IL-10 produced by PBMC obtained at peak
rickettsemia.
Effect of mixing responding and nonresponding PBMC
To determine whether the MSP2-nonresponsive cells from the
peak of rickettsemia contained a population of cells that were sup-
pressive, proliferation assays were performed using a fixed number
of responding cells obtained before peak rickettsemia mixed with
increasing numbers of nonresponding cells obtained at or after
peak rickettsemia (Fig. 5). No significant inhibition of PBMC re-
sponses was observed when cells from four different animals were
tested in repeated assays. The results for animals 71 and 82 are
shown in Fig. 5.
Positively selected CD4! T cells from peak rickettsemia do not
respond to Ag cultured with APC from naive donors
To address the possibility that the inability to detect a CD4! T cell
response following challenge was caused by dysfunctional APC,
CD4! T cells were positively selected from PBMC of two animals
(71 and 76) cryopreserved at time points when the cells responded
or at peak rickettsemia when no response was detected. PBMC
were stimulated with Ag in the presence of MHC class II DRB3
homozygous and half-matched APC from A. marginale naive do-
nor cattle. CD4! T cells obtained at time points where responses
to Ag were previously observed had strong and significant prolif-
erative responses to A. marginale and MSP2 in the presence of
APC from naive donors (Table VII). In contrast, CD4! T cells
obtained at the peak of infection had undetectable proliferative
Table IV. Percentage of CD25!CD4! T cells in PBMC from cattle during acute anaplasmosis: percentage of cell types in total PBMC as
determined by flow cytometric analysis a
Immunization Group Animal Time CD4! and CD25! CD3! and CD4! CD3! and CD25!
IL-12 71 Prepeakb ND 15 17
Alum Peak ND 7 4
MSP2 Postpeak ND 11 15
75 Prepeak 3 16 14
Peak 2 16 10
Postpeak 5 19 20
76 Prepeak 4 22 11
Peak 2 25 3
Postpeak 3 25 6
82 Prepeak 1 17 7
Peak 1 13 5
Postpeak 2 2 4
CpG 78 Prepeak 3 13 2
Alum Peak 1 11 4
MSP2 Postpeak 3 15 12
79 Prepeak 1 14 2
Peak 1 8 3
Postpeak 1 14 5
81 Prepeak 2 13 13
Peak 2 11 4
Postpeak 7 23 4
87 Prepeak 1 13 3
Peak 1 9 5
Postpeak 3 15 5
CpG 73 Prepeak 2 16 11
Alum Peak 1 11 5
No MSP2 Postpeak 2 21 9
74 Prepeak 1 17 5
Peak 1 13 5
Postpeak 1 16 4
84 Prepeak ND ND ND
Peak ND ND ND
Postpeak ND ND ND
89 Prepeak 18 11 20
Peak 1 11 2
Postpeak 3 23 8
No immunization
nor infection
80 3 17 3
a FACs analysis was done using frozen PBMC from three time points following challenge with 3000 live A. marginale organisms. mAb ILA11 (CD4) and CACT116A
(CD25), and MM1A (CD3) were used for dual color staining.
b Time points are prepeak rickettsemia, peak rickettsemia (Peak), and postpeak rickettsemia.
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responses to Ag, but did proliferate to TCGF, as observed when
autologous APC were used to present Ag.
Inhibition of lymphocyte viability and proliferation by A.
marginale in vitro
One possible explanation for the loss of A. marginale MSP2-spe-
cific responses following challenge is that the high level of rick-
ettsemia resulted in deletion of specific cells. We had observed that
concentrations of A. marginale Ag (e.g., '25 #g/ml) were often
inhibitory when T lymphocyte proliferation assays were performed
(33). To determine the effect of A. marginale on lymphocyte via-
bility and proliferation to TCGF in vitro, purified initial bodies
ranging from the equivalent of 3 # 106 to 5 # 107 organisms/ml
(5–80 #g/ml protein) were cultured with PBMC from a naive an-
imal in the presence of 10% TCGF. A. marginale inhibited both
cell viability and proliferation to TCGF in a dose-dependent man-
ner (Fig. 6).
Discussion
The results of this study do not support our hypothesis that chal-
lenge with A. marginale expressing MSP2 variants to which the
animals had been previously exposed would stimulate strong an-
amnestic CD4! T cell and IgG responses directed against con-
served and variant-specific epitopes that would be associated with
variant-specific organism clearance. In contrast, analysis of the
immune response upon challenge demonstrates a newly discovered
modulation whereby Ag-specific T cell responsiveness induced by
vaccination is lost upon rickettsial challenge.
Sequencing of msp2 transcripts from the blood of cattle obtained
during ascending and peak rickettsemia ruled out the possibility
that acute rickettsemia resulted from selective expansion either of
organisms expressing variants of MSP2 that constituted a minor
population in the challenge inoculum, or of organisms expressing
novel msp2 sequences. This indicates that either the MSP2-specific
immune response induced by immunization or the recall response
elicited by the challenge was insufficient to effect clearance.
The lack of strong recall T cell responses to MSP2 following A.
marginale infection may be related to the uniformly dramatic loss
of MSP2-specific CD4! T cell responses that occurred in all an-
imals concurrently with development of measurable rickettsemia.
However, the sustained Th cell response for the first 3 wk follow-
ing challenge was apparently sufficient to stimulate a boost in IgG
production. This infection-mediated immune modulation of a
strong CD4! T cell response directed against multiple antigenic
epitopes (25) has not been previously described for any rickettsial
pathogen. However, in other persistent pathogen infection models,
anergy induced by altered peptide ligand antagonism (41–43), or
by T regulatory cells producing either TGF-$1 or IL-10 (37, 44–
49), has been shown to play a role in down-regulating T cell re-
sponses. Although antigenically variant MSP2 epitopes could po-
tentially act as antagonistic peptides, previous studies did not show
the ability of naturally occurring variant epitopes to cause anergy
of MSP2-specific T cell lines or clones specific for the agonistic
MSP2 variant (10). Furthermore, the disappearance of T cell re-
sponses to conserved MSP2 epitopes, as well as variable MSP2
epitopes, argues against antigenic variation in MSP2 as a reason
for the abrupt loss of T cell responsiveness.
To address the possibility that A. marginale infection induced a
T regulatory cell response, experiments were performed to deter-
mine changes in the percentage of CD25!CD4! T cells during the
course of infection, to examine IL-10 and TGF-$1 production by
responding and nonresponding cells, to detect the presence of a
population of suppressive cells in peripheral blood by mixing re-
sponding and nonresponding cells, and to test positively selected
CD4! T cells. Although our results do not support the role of T
regulatory cells in the dramatic loss of MSP2-specific CD4! T cell
immune responses, their role cannot be definitively ruled out, be-
cause these cells have not been phenotypically characterized in
cattle. We were similarly unable to demonstrate a shift from a
dominant IFN-" Th1 response (28) response to an IL-4 dominant
response following challenge.
To test the possibility that infection impaired APC to present A.
marginale Ag to CD4! T cells, positively selected CD4! T cells
Table VI. Comparison of cytokines IL-10, TGF-$1, and IL-4 in culture
supernatants from responding and nonresponding PBMC stimulated with
MSP2: average responses from all animalsa
Cytokine Average SD t test ( p &)
IL-10
Pre 20 19 0.04
Peak 5 4
TGF-$
Pre 1324 527 0.20
Peak 1617 892
IL-4
Pre 190 117 0.07
Peak 250 122
a Amount of cytokine is described in Table V. The responses from all immunized
animals were averaged and tested for statistical significance using a paired two-tailed
t test. p values are shown.
Table V. Comparison of cytokines IL-10, TGF-$1, and IL-4 in culture supernatants from responding and nonresponding PBMC stimulated with
MSP2: the mean cytokine concentration ! 1 SD in supernatants of PBMC from the animalsa
Cytokineb cRPMIc PMAd
IL-12 Group CpG Group
Animal 71 Animal 75 Animal 76 Animal 82 Animal 78 Animal 79 Animal 81 Animal 87
Prepeak Peak Prepeak Peak Prepeak Peak Prepeak Peak Prepeak Peak Prepeak Peak Prepeak Peak Prepeak Peak
IL-10
U/ml (SD)
0
(0)
225
(24)
43
(3)
9
(1)
23
(4)
5
(7)
22
(3)
0
(0)
8
(0)
9
(13)
0
(0)
8
(4)
52
(4)
0
(0)
13
(0)
6
(0)
0
(0)
3
(4)
TGF-$
pg/ml (SD)
1171
(167)
2436
(184)
364
(226)
1412
(8)
1021
(1449)
642
(142)
1217
(1105)
3165
(42)
1092
(50)
1400
(1080)
1885
(706)
1373
(605)
2015
(252)
2723
(883)
1575
(958)
702
(227)
1421
(420)
1516
(1345)
IL-4
pg/ml (SD)
116
(15)
402
(99)
104
(102)
28
(5)
60
(10)
187
(25)
344
(33)
384
(27)
99
(55)
349
(38)
177
(9)
286
(30)
386
(18)
357
(86)
166
(1)
147
(5)
180
(7)
258
(6)
a Cryopreserved PBMC from MSP2 vaccinates prior to (pre) or at peak rickettsemia were cultured for 72 h with 10 #g/ml MSP2.
b Optimal supernatant dilutions are shown, which were 1/2 for IL-10, 1/16 for TGF-$1, and 1/10 for IL-4.
c Negative controls are supernatants from PBMC cultured with complete RPMI 1640 (cRPMI) alone.
d Positive controls are supernatants from PBMC from a naive animal stimulated with PMA plus ionomycyin for 72 h.
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were cultured with Ag in the presence of class II-compatible APC
from noninfected donors. However, T cells obtained at the peak of
infection were still unable to respond to Ag, ruling out dysfunc-
tional APC as the reason for the sudden loss of response.
Sheep and dogs infected with Anaplasma phagocytophilum de-
velop a transient immunosuppression defined by leukopenia (re-
duced numbers of T lymphocytes and neutrophils) and an in-
creased susceptibility to other infectious organisms (50–52). A.
phagocytophilum infects neutrophils and alters neutrophil function
(53–57), which may explain the transient generalized immune sup-
pression. However, a similar mechanism of generalized immune
suppression by A. marginale is unlikely for the following reasons:
1) this pathogen infects erythrocytes and not neutrophils, 2) the
response to unrelated clostridial Ags was not severely impaired
during acute infection, and 3) increased susceptibility to unrelated
or opportunistic infections has not been reported for cattle with
anaplasmosis.
The unsubstantiated role of T regulatory cells in the disappear-
ance of the MSP2-specific memory T cell response, the lack of
evidence for altered Ag presentation, and the Ag-specific nature of
Table VII. CD4! T cells obtained at the peak of rickettsemia fail to proliferate to A. marginale MSP2 in the presence of normal APC
Antigen
Proliferation (mean cpm % 1 SD) of CD4! T Cells Obtained froma
Animal 71 (DRB3 8/14) Animal 76 (DRB3 22/21)
Prepeak Peak Prechallenge Peak
Medium 762% 52 133 % 27 1,302 % 497 354 % 32
TCGF 103,012 $ 1,038 91,768 $ 2,276 78,037 $ 5,267 16,190 $ 1,647
URBC 849% 726 85 % 39 1,363 % 636 323 % 119
A. marginale 56,507 $ 2,354 29 % 22 10,544 $ 753 132 % 51
MSP2 60,906 $ 4,724 48 % 28 26,174 $ 7,580 322 % 224
a CD4! T cells were obtained by positive selection from PBMC from animals 71 and 76 cryopreserved at 1 wk postchallenge (animal 71) or 2 wk prechallenge (animal 76)
or at peak rickettsemia and cultured with APC from MHC class II homozygous and half-matched normal donors. For 71 T cells, APC from animal 98B61 (DRB3 8/8) were used,
and for 76 T cells, APC from animal 201 (DRB3 22/22) were used. Cells were cultured with medium, 10% TCGF, or 10 #g/ml the indicated Ags, and results are presented as
the mean cpm % 1 SD of triplicate cultures. Numbers in boldface type are significantly greater than those for URBC or medium controls ( p ( 0.01).
FIGURE 5. Mixing assays of nonresponding and re-
sponding PBMC stimulated with 5 #g/ml MSP2. Non-
responding PBMC (NR-PBMC) obtained from animals
during peak rickettsemia were cultured at ratios of 4:1,
2:1, 1:1, 0.5:1, or 0:1 with a constant number of re-
sponding PBMC (R-PBMC) obtained from animals be-
fore peak rickettsemia. Responding PBMC from animal
71 were cultured at 1 # 105 cells/well (A) and respond-
ing PBMC from animal 82 were cultured at 0.5 # 105
cells/well (B).
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the immune suppression suggest an alternative mechanism for the
loss of T cell responsiveness. One potential mechanism is periph-
eral T cell deletion that could occur via activation-induced cell
death (AICD) following organism challenge (58). During primary
HIV infection, naturally induced HIV-specific CD8! T cell clones
with defined TCR V$ usage were shown to rapidly disappear,
independent of changes in the viral epitopes recognized (59). An
unrelated study reported in vivo elimination of Ag-specific Th1
cells, obtained from TCR transgenic mice that were adoptively
transferred to normal mice, following i.v. challenge with the Ag
cytochrome c 1–2 mo later (60). The Ag-specific memory T cells
became rapidly activated in vivo upon Ag administration, but by
day 8 following Ag challenge, declined to barely detectable num-
bers and remained depressed or anergic for 3 mo. The authors
concluded that Ag challenge of resting Th1 CD4! T cells led to
transient activation followed by cell depletion. In our studies, A.
marginale was administered i.v. and the infection took "5 wk to
reach peak levels in peripheral blood. Thus, for the first 3 wk
following challenge, recall T cell responses remained at prechal-
lenge levels, but were completely undetectable at the peak of in-
fection, 2 wk later. We therefore examined CD4! T cell IFN-"
ELISPOT responses in six immunized cattle at "1 wk before the
peak of infection was reached (29 or 31 DPI), and observed weakly
positive responses in two animals and undetectable responses in
four animals (data not shown). These results are consistent with
Ag-induced AICD. Furthermore, A. marginale inhibited, in a dose-
dependent manner, proliferation of lymphocytes that paralleled a
loss in cell viability. A reduction in the response to TCGF from
'50 to 100% was observed at organism concentrations equivalent
to those observed at peak levels of rickettsemia in vivo following
challenge, which ranged from 1 # 107 to 8 # 108 organisms per
milliliter of blood (Fig. 2). However, the significance of these in
vitro results to the in vivo infection is not clear, because A. mar-
ginale is generally intraerythrocytic and the nature of the interac-
tion of infected erythrocytes with T cells is unknown. Neverthe-
less, these results are also consistent with a loss in immune
responsiveness as a consequence of increasing Ag dose in vivo,
and a mechanism of AICD.
In conclusion, we hypothesize that MSP2-specific memory T
cells were deleted or decreased to undetectable numbers in animals
following infection with A. marginale. Our data indicate a newly
discovered immune modulation whereby Ag-specific T cell re-
sponsiveness is lost upon rickettsial challenge. MSP-2-specific T
cells may be deleted as a consequence of high levels of Ag oc-
curring during ascending rickettsemia, and the number of MSP2-
specific T cells may remain depressed as a result of the chronic low
antigenic exposure during persistent infection. Consistent with this
is our inability to detect CD4! T cell responses in nonimmunized
cattle following either i.v. or tick-transmitted A. marginale chal-
lenge for up to 3 mo postinfection (this study and our unpublished
observations). Additional experiments using MHC class II tetram-
ers to track the fate of epitope-specific T cells in immunized and
control cattle during acute and chronic anaplasmosis should clarify
the mechanism for the loss of Ag-specific T cell responses follow-
ing A. marginale infection and determine whether a similar im-
mune modulation occurs during infection of nonvaccinated cattle.
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